IBO News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IB

Mkt Cap

$23.0M

Volume

9.92K

Next Earnings

November 6th

Loading chart

IB

IBOImpact BioMedical, Inc.

IBO

Pay with—

Available Balance0.00

IB

Mkt Cap

$22.9M

Volume

9.92K

Next Earnings

November 6th

Chart Financials Earnings News About Insider Filings

CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)Impact Biomedical Inc (NYSE: IBO) announced a 1 for 12.62 reverse stock split effective September 23, 2026, to support its proposed merger with Zoar Limited. The merger exchange ratio was corrected to 1 share of Zoar for every 1 share of Impact stock (post-split). Upon completion, the combined entity will focus on developing and supplying Active Pharmaceutical Ingredients for special therapeutic areas.GlobeNewswire Inc. · Sep 15, 2026

ImPact Biotech Presents Updated Data from Phase 1 Trial of Padeliporfin VTP in LA-PDAC and Phase 3 ENLIGHTED Trial in LG-UTUC at ASCO 2026ImPact Biotech announced updated clinical trial data for Padeliporfin VTP, a vascular-targeted photodynamic therapy. In the Phase 1 LA-PDAC trial, 71% of patients (5/7) achieved successful surgical resection with a well-tolerated safety profile. The Phase 3 ENLIGHTED trial in LG-UTUC showed 70% complete response rates with 85.7% of patients sustaining responses for at least 12 months. The company plans to submit an NDA for LG-UTUC in 2027 and is exploring potential accelerated registrational pathways for LA-PDAC.GlobeNewswire Inc. · May 30, 2026

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026ImPact Biotech announced updated Phase 3 ENLIGHTED trial results for Padeliporfin VTP in low-grade upper tract urothelial cancer, showing 70% complete response rate in 72 evaluable patients and 85.7% durability at 12 months. The treatment demonstrated a consistent safety profile with mostly mild to moderate adverse events. Topline data expected later in 2026 with regulatory submission planned for 2027.GlobeNewswire Inc. · May 16, 2026

Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger PlansImpact BioMedical Inc. (NYSE American: IBO) received a 'going concern' qualification in its 2025 10-K audit opinion from Grassi & Co., CPAs, indicating substantial doubt about the company's ability to continue operations. Despite this financial concern, the company continues pursuing a strategic merger with Dr. Ashley's Ltd., projected to close by July 1, 2026.GlobeNewswire Inc. · Apr 3, 2026

Impact Biomedical (IBO) Stock Jumps Over 86% After Hours — Here's WhyImpact Biomedical (IBO) shares surged 86.28% in after-hours trading to $0.77 following an SEC filing that disclosed amendments to its pending merger with Dr Ashleys Bio Labs Limited. The merger agreement was extended from March 31 to July 1, 2026, with revised share allocations. Dr Ashleys will issue 169.5 million shares (94.20% of total), while parent company DSS will receive 53,000 shares with potential for 75,000 additional shares if funding obligations are met.Benzinga · Mar 5, 2026

DSS, Inc.'s Subsidiary, Impact BioMedical Inc., Announces Strategic MergerDSS, Inc. announced that its subsidiary, Impact BioMedical Inc., has entered into a definitive merger agreement with Dr. Ashleys Limited, a global pharmaceutical company. The transaction will result in a newly formed combined entity traded on the NYSE American under the name 'Dr Ashleys Limited'.Benzinga · Jun 24, 2025

Impact Biomedical Inc. Announcement Stock Activity/PricingImpact BioMedical Inc. announced that there has been no material development in its business affairs not previously disclosed or any other reason to account for the unusual market action regarding its share price.GlobeNewswire Inc. · Mar 21, 2025

Impact Biomedical Inc. Announces Acquisition of Celios®, "Protecting People, Plants, and Animals from the World's Most Dangerous Pathogens With Clean-Room Air Quality"Impact Biomedical Inc. has acquired Celios®, a pioneering air purification technology company, in a strategic all-equity transaction. The acquisition aligns with Impact Biomedical's strategy to expand its portfolio with cutting-edge solutions that generate immediate revenue and reinforce its commitment to human health and wellness.Benzinga · Feb 26, 2025

Contractor Wins Prestigious Award for Exquisite Ornamental StaircaseMcGregor Industries, a Pennsylvania-based contractor, won the IMPACT Project of the Year award in the Architectural/Ornamental category for its work on the Raffles 17th Floor Lobby Stairs, a complex and monumental two-story, elliptical, bronze-finished stair and railing project.GlobeNewswire Inc. · Dec 12, 2024

ImPact Biotech to Present Updated Interim Phase 3 Data from ENLIGHTED Study of Padeliporfin VTP in Low Grade UTUC at EMUC 2024ImPact Biotech, a clinical-stage biotechnology company, announced that it will present interim results from its ongoing Phase 3 study of Padeliporfin VTP treatment for low-grade upper tract urothelial cancer (UTUC) at the EMUC 2024 conference.GlobeNewswire Inc. · Oct 25, 2024

to start trading

IB

IBOImpact BioMedical, Inc.

IBO

Pay with—

Available Balance0.00

Your PositionYou don't own any IBO yet.

Related Tickers

Earnings